摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-hydroxy-2-[[(4-phenoxyphenyl)-sulfonyl]methyl]benzamide | 213012-57-8

中文名称
——
中文别名
——
英文名称
N-hydroxy-2-[[(4-phenoxyphenyl)-sulfonyl]methyl]benzamide
英文别名
N-Hydroxy-2-[(4-phenoxybenzene-1-sulfonyl)methyl]benzamide;N-hydroxy-2-[(4-phenoxyphenyl)sulfonylmethyl]benzamide
N-hydroxy-2-[[(4-phenoxyphenyl)-sulfonyl]methyl]benzamide化学式
CAS
213012-57-8
化学式
C20H17NO5S
mdl
——
分子量
383.425
InChiKey
JDRAWZOVTMVGBI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3
  • 重原子数:
    27
  • 可旋转键数:
    6
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.05
  • 拓扑面积:
    101
  • 氢给体数:
    2
  • 氢受体数:
    5

文献信息

  • Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
    申请人:——
    公开号:US20030171404A1
    公开(公告)日:2003-09-11
    This invention is directed to a process for inhibiting aggrecanase activity. The process comprises administering a therapeutically effective amount of a sulfonyl aromatic or heteroaromatic hydroxamic acid, a derivative thereof, or a pharmaceutically acceptable salt of the hydroxamic acid or derivative to a host animal. The compound generally corresponds in structure to the following formula: 1 wherein W and the R groups are described in more detail in Applicants' specification.
    这项发明涉及一种抑制聚集素酶活性的过程。该过程包括向宿主动物施用一定治疗有效量的磺酰芳香或杂芳羟肟酸、其衍生物或羟肟酸或其衍生物的药用盐。该化合物通常与以下结构对应:1其中W和R基的详细描述在申请人的说明书中。
  • Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
    申请人:——
    公开号:US20030073845A1
    公开(公告)日:2003-04-17
    This invention is directed to sulfonyl aromatic hydroxamic acid compounds and salts thereof that, inter alia, inhibit matrix metalloprotease (MMP) activity and/or aggrecanase activity. In some particularly preferred embodiments, the compound corresponds in structure to one of the following formulas: 1 wherein W 2 , the R groups, and —A—R—E—Y are described in more detail in Applicants' specification. This invention also is directed to a process that comprises administering such a compound or pharmaceutically acceptable salt thereof to a host animal having a condition associated with MMP activity.
    本发明涉及磺酰基芳基羟肟酸化合物及其盐,这些化合物在抑制基质金属蛋白酶(MMP)活性和/或聚集素酶活性方面具有作用。在一些特别优选的实施方式中,该化合物的结构符合以下公式之一:其中W2、R基团和—A—R—E—Y在申请人的说明书中有更详细的描述。本发明还涉及一种过程,该过程包括向患有与MMP活性相关的病况的宿主动物施用这种化合物或其药用可接受盐。
  • Sulfonyl aryl or heteroaryl hydroxamic acid compounds
    申请人:Bedell J. Louis
    公开号:US20050075374A1
    公开(公告)日:2005-04-07
    A sulfonyl aromatic or heteroaromatic ring hydroxamic acid compound that inter alia inhibits matrix metalloprotease activity is disclosed as are a treatment process that comprises administering a contemplated sulfonyl aromatic or heteroaromatic ring hydroxamic acid compound in a MMP enzyme-inhibiting effective amount to a host having a condition associated with pathological matrix metalloprotease activity.
    本发明涉及一种磺酰基芳香族或杂芳香族环羟肟酸化合物,该化合物在抑制基质金属蛋白酶活性等方面具有作用。本发明还涉及一种治疗方法,该方法包括向患有与病理性基质金属蛋白酶活性相关的疾病的宿主中,以MMP酶抑制有效量的考虑中的磺酰基芳香族或杂芳香族环羟肟酸化合物进行治疗。
  • SULFONYL DIVALENT ARYL OR HETEROARYL HYDROXAMIC ACID COMPOUNDS
    申请人:——
    公开号:US20010020021A1
    公开(公告)日:2001-09-06
    A sulfonyl divalent aromatic or heteroaromatic ring hydroxamic acid compound that inter alia inhibits matrix metalloprotease activity is disclosed as are a treatment process that comprises administering a contemplated sulfonyl divalent aromatic or heteroaromatic ring hydroxamic acid compound in a MMP enzyme-inhibiting effective amount to a host having a condition associated with pathological matrix metalloprotease activity.
    本文披露了一种磺酰基双价芳香或杂芳香环羟肟酸化合物,其可以抑制基质金属蛋白酶活性,同时也揭示了一种治疗过程,包括向患有与病理基质金属蛋白酶活性相关的病情的宿主中投与考虑的磺酰基双价芳香或杂芳香环羟肟酸化合物,其剂量具有抑制MMP酶活性的有效作用量。
  • Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds
    申请人:——
    公开号:US20020103239A1
    公开(公告)日:2002-08-01
    A sulfonyl divalent aromatic or heteroaromatic ring hydroxamic acid compound that inter alia inhibits matrix metalloprotease activity is disclosed as are a treatment process that comprises administering a contemplated sulfonyl divalent aromatic or heteroaromatic ring hydroxamic acid compound in a MMP enzyme-inhibiting effective amount to a host having a condition associated with pathological matrix metalloprotease activity.
    公开了一种特别能抑制基质金属蛋白酶活性的磺酰二价芳香族或杂芳环状羟肟酸化合物,以及一种治疗方法,该方法包括向患有与病理性基质金属蛋白酶活性有关的病症的宿主施用有效量的MMP酶抑制剂磺酰二价芳香族或杂芳环状羟肟酸化合物。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐